Pharmacology and Pathophysiology2 Calcium ions act as neural transmitters where they are stimulated by action potential enabling them to open voltages dependant calcium Channels (Hsu, Lane and Lin, 2018) In neurons, calcium ions acts as transmitters where they can alter the electrical conductivity by modifying the closing of sodium and potassium channels in order to stimulate the release of a neural transmitter substances (Popugaeva, Pchitskaya, and Bezprozvanny, 2017) . This, in turn, leads to calcium ions mediated abnormalities that can lead to a disease.As a result, calcium ions dysregulation is involved in Alzheimer's disease(Small, 2009). Various amyloid proteins have been proved to be involved in the induction of calcium ions influx into neurons, making this calcium reflux alters neurological excitability.There are various drugs used in the treatment of the disease namely Cholinesterase inhibitors and memantine (Downey, 2013). Cholinesterase inhibitors prevent the break down of acetylcholine, delay worsening and are generally tolerated. Memantine, on the other hand, acts by helping to improve memory, reasoning, language and increase people performance of little tasks (Downey, 2013). The memantanemedication acts to regulate the activity of glutamate a chemical that is used in processing, storage, and retrieval of information(Marum, 2014). On the other hand, cholinesterase inhibitors act toprevent the break down of acetylcholine which is usually crucial in learning and memory (Downey, 2013). The drug also slow worsening of the symptoms and their complications are well tolerated(Small, 2013). These drugs include Donepezil, rivastigmine, and galantamine. The relevance of this study to the field of nursing include it help nurse to understand the effect of calcium in a patient with Alzheimer disease and offer a gap for research. Other than that, nurses and patients are able to understand different types of drugs available for treatment and their side effects and precautions.
Pharmacology and Pathophysiology3
Pharmacology and Pathophysiology4 References Amidfar, M., Kim, Y. and Wiborg, O. (2018). The effectiveness of memantine on depression- like behavior, memory deficits and brain mRNA levels of BDNF and TrkB in rats subjected to repeated unpredictable stress.Pharmacological Reports, 70(3), pp.600-606. Alzheimer's Association. (2018).Latest Medication for Memory Loss | Alzheimer's Association. Available at: https://www.alz.org/alzheimers_disease_standard_prescriptions.asp Dyer, S., Harrison, S., Laver, K., Whitehead, C. and Crotty, M. (2017). An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia.International Psychogeriatrics, 30(03), pp.295-309. Downey, D. (2013). Pharmacologic Management of Alzheimer Disease.Journal of Neuroscience Nursing, 40(1), pp.55-59. Hsu, W., Lane, H. and Lin, C. (2018). Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease.Frontiers in Psychiatry, 9.
Paraphrase This Document
Need a fresh take? Get an instant paraphrase of this document with our AI Paraphraser
Pharmacology and Pathophysiology5 Marum, R. (2014). Update on the use of memantine in Alzheimer’s disease.Neuropsychiatric Disease and Treatment, p.237. Popugaeva, E., Pchitskaya, E. and Bezprozvanny, I. (2017). Dysregulation of neuronal calcium homeostasis in Alzheimer's disease – A therapeutic opportunity?.Biochemical and Biophysical Research Communications, 483(4), pp.998-1004. Popugaeva, E., Vlasova, O. and Bezprozvanny, I. (2015). Restoring calcium homeostasis to treat Alzheimer's disease: a future perspective.Neurodegenerative Disease Management, 5(5), pp.395-398. Small, D. (2013). Dysregulation of Calcium Homeostasis in Alzheimer’s Disease.Neurochemical Research, 34(10), pp.1824-1829.